Selected article for: "binding domain and domain close"
Author: Poh, Chek Meng; Carissimo, Guillaume; Wang, Bei; Amrun, Siti Naqiah; Lee, Cheryl Yi-Pin; Chee, Rhonda Sin-Ling; Fong, Siew-Wai; Yeo, Nicholas Kim-Wah; Lee, Wen-Hsin; Torres-Ruesta, Anthony; Leo, Yee-Sin; Chen, Mark I-Cheng; Tan, Seow-Yen; Chai, Louis Yi Ann; Kalimuddin, Shirin; Kheng, Shirley Seah Gek; Thien, Siew-Yee; Young, Barnaby Edward; Lye, David C.; Hanson, Brendon John; Wang, Cheng-I; Renia, Laurent; Ng, Lisa F. P.
Title: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
  • Cord-id: p9u6rlue
  • Document date: 2020_6_1
    • ID: p9u6rlue
    Snippet: Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is l
    Document: Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus.

    Search related documents:
    Co phrase search for related documents
    • accession number and acute respiratory syndrome coronavirus: 1, 2, 3
    • accession number and luciferase reporter: 1
    • acute respiratory and live sars virus neutralisation: 1
    • acute respiratory and low level albeit: 1
    • acute respiratory and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute respiratory and luciferase assay system: 1
    • acute respiratory and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lysis buffer: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and mabs isolation: 1
    • acute respiratory and mabs potential monoclonal antibody: 1
    • acute respiratory syndrome coronavirus and live sars virus neutralisation: 1
    • acute respiratory syndrome coronavirus and low level albeit: 1
    • acute respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome coronavirus and luciferase assay system: 1
    • acute respiratory syndrome coronavirus and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory syndrome coronavirus and lysis buffer: 1, 2, 3
    • acute respiratory syndrome coronavirus and mabs isolation: 1
    • acute respiratory syndrome coronavirus and mabs potential monoclonal antibody: 1
    • luciferase activity and lysis buffer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14